Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorEmory University

About this trial

This study is evaluating an investigational drug, eptacog beta (EB), for the treatment and prevention of acute bleeding episodes in people with Glanzmann Thrombasthenia, a rare inherited bleeding disorder. Eptacog beta (EB) is not currently approved by the U.S. Food and Drug Administration (FDA) for this condition.

The study will assess the effectiveness and safety of eptacog beta (EB) when used to treat serious bleeding events, and in an optional phase, when used routinely to prevent bleeding. During the first three (3) months, participants will manage any bleeding episodes with their standard treatment (e.g., factor products or platelet transfusions). After this initial period, they will use the study drug to treat serious bleeding events.

Participants will have approximately 4 to 5 visits with their hematologist over the 9-month study period. They will also be asked to complete a diary documenting bleeding episodes and treatments, and to answer questions about how bleeding affects their daily life. Blood samples will be collected to monitor their condition and any potential side effects of the study drug.

At the end of the main study, participants will have the option to enter an optional extension phase, where they will receive routine intravenous infusions of the study drug 2 to 3 times per week for 6 months to help prevent future bleeding episodes and complications.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult or Pediatric persons with inherited Glanzmann thrombasthenia (see diagnostic criteria below)

Severe bleeding phenotype

Adequate hepatic function

Adequate renal function

Disqualifiers

Thrombocytopenia (platelet count < 100k)

Acquired Glanzmann thrombasthenia secondary to autoimmune disease, malignancy, or medication

Inherited or acquired bleeding diathesis other than Glanzmann thrombasthenia

Have a history of venous or arterial thrombotic event within 2 years of study enrollment

Trial design

Design model

Single group

Treatments tested in this trial

  • EPTACOG BETA

    Drug

    Eptacog beta (SEVENFACT®; EB) is a lyophilized powder in single-use vials (1, 2, or 5 mg) of coagulation factor VIIa (recombinant)-jncw. It is reconstituted with sterile water (provided in the kit) and administered intravenously. SEVENFACT® may be administered by a healthcare provider (HCP) at the study site or home, or by a trained participant/caregiver. Participants will be monitored in a healthcare facility for 60 minutes after the first dose for hypersensitivity.

Treatment groups

6 Participants
are divided into 1 treatment group
Group A: Eptacog betaExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Proportion of bleeding events successfully treated within 24 hours of the first Eptacog Beta (EB) administration

Proportion of acute bleeding events successfully treated with EB within 24 hours of the first EB administration based on an "excellent or good" response on a 4-point hemostatic efficacy scale and without rebleeding before 36 hours. Hemostatic Efficacy Scale: None = No effect; bleeding unchanged or worsened; continued treatment needed. Moderate = Some effect (e.g., pain decreased, bleeding signs improved) but bleeding continued; further treatment needed. Good = Bleeding symptoms are largely reduced but not completely resolved; no further EB infusions are needed. Excellent = Full relief of bleeding symptoms; no additional EB infusion required.

Time frame
24 hours after the first EB dose administration
2

Number of bleeding events over the study period

The number of bleeding events occurring while receiving routine EB prophylaxis will be compared with the number of bleeding events that occurred during on-demand therapy. \*This outcome applies only to the optional interventional prophylaxis phase.

Time frame
6 months following the start of the interventional prophylaxis phase

Secondary outcomes

1

Number of treatment-Emergent Adverse Events and Clinically Significant Laboratory Abnormalities

Safety of EB will be measured by the number of treatment-emergent adverse events, treatment-emergent serious adverse events, and treatment-emergent potentially clinically significant laboratory values reported during the interventional phases compared to those reported during the non-interventional observational phase.

Time frame
6 months following the start of EB administration for each study phase
2

EuroQol five-dimensional questionnaire for youth (EQ-5D-Y) score for participants 4-15 years of age.

The EQ-5D-Y-5L is a child-friendly, five-dimension, five-level instrument assessing: Mobility, Looking After Myself, Doing Usual Activities, Having Pain or Discomfort, and Feeling Worried, Sad, or Unhappy. Each dimension has five response levels (1 = no problems to 5 = extreme problems/unable to do). Respondents select one statement per dimension describing their health on the assessment day, forming a 5-digit profile summarizing their health state. For example, code 11234 indicates no problems with mobility or looking after myself, slight problems doing usual activities, some pain or discomfort, and feeling very worried, sad, or unhappy. Higher scores reflect greater severity. \*15 months applies to the optional phase only.

Time frame
Baseline, 9 and 15 months after baseline
3

EuroQol five-dimensional 5 Level (EQ-5D-5L) score for participants ≥16 years

The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It captures how people feel across five dimensions, each of which has five levels: 1 = no problems to 5 = extreme problems/unable to do. The five answers produce a unique 5-digit health state, for example, 11234, that describes the young person's health state. For example, the code 11234 describes a health state where there are no problems with walking about (mobility) or looking after myself, a little bit of a problem with doing usual activities, some pain or discomfort, and feeling really worried, sad, or unhappy. \*15 months applies to the optional phase only.

Time frame
Baseline, 9 and 15 months after baseline
4

Patient Reported Outcomes Measurement Information System (PROMIS) fatigue short form for adults

The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The fatigue short forms are universal and assess fatigue over the past seven days. PROMIS measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. Higher scores equal more fatigue. \*15 months applies to the optional phase only.

Time frame
Baseline, 9 and 15 months after baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Emory University

Lead sponsor

Laboratoire français de Fractionnement et de Biotechnologies

Collaborator